BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 1, 2017
View Archived Issues
Benitec Biopharma begins work on two HNSCC programs
Read More
Onxeo and Institut Curie to study combining radiotherapy, DNA repair inhibitors and immunotherapy
Read More
Celgene reviews pipeline highlights of fourth quarter 2016
Read More
Phase I larotrectinib results presented at ECCO 2017
Read More
DOCK6 as an independent marker of tumor progression in gastric cancer
Read More
SETDB1 as a novel prognostic factor and potential therapeutic target in gastric cancer
Read More
Dimension Therapeutics reports topline results from phase I/II program of lead AAV candidate
Read More
Novel fragment-based screening platform for ligand and target discovery
Read More
Novel MN-array patch effectively regulates glucose levels and reduces risk of hypoglycemia in vivo
Read More
Grifols completes acquisition of Hologic NAT donor screening unit
Read More
Quadracel DTaP-IPV vaccine for children 4 through 6 years of age becomes available in the U.S.
Read More
Canada first to approve Kevzara
Read More
Catabasis reports topline results from Part B of MoveDMD study of edasalonexent
Read More
MediWound's phase II study of EscharEx meets primary endpoint
Read More
Novartis reviews pipeline progress of fourth quarter 2016
Read More
Merck KGaA discloses novel BTK inhibitors
Read More
Janssen Pharmaceutica identifies NR2B receptor antagonists
Read More
Japanese phase III trial of KHK-7580 in secondary hyperparathyroidism meets primary endpoint
Read More
Keytruda approved for first-line treatment of metastatic NSCLC in E.U.
Read More
Bayer patents mutant IDH1 inhibitors
Read More
Roche presents novel glutamate transporter EAAT3 inhibitors
Read More
Heptares Therapeutics launches new research collaboration with University of Cambridge
Read More
FDA accepts OptiNose's NDA for OPN-375
Read More
MISSION Therapeutics discloses novel deubiquylating enzymes inhibitors
Read More
First patient dosed in Angion Biomedica's phase II study of BB3
Read More
Spero Therapeutics acquires next-generation antibacterial candidates from Pro Bono Bio
Read More
Gemphire Therapeutics reports interim data from phase IIb study of gemcabene in HoFH
Read More
Tenax reports topline data from phase III trial of levosimendan in cardiac surgery
Read More